Entity family

Browse diseases

Named diseases, disorders, syndromes, injuries, and health conditions. Examples include epilepsy, diabetes, stroke.

17articles mentioning diseases

48disease mentions

1distinct diseases extracted

0%of mentions human-reviewed

Active filtersEntity: mCRPC ×

mCRPC

This disease is selected. Its supporting articles are shown below.

Articles mentioning mCRPC

17 articles · page 2 of 2

499 Phase 2 trial of pTVG-HP DNA vaccine, with or without pTVG-AR DNA vaccine, and pembrolizumab in patients with castration-resistant, metastatic prostate cancer

jitc · abstract · 2025-11-04 · 2 matching annotations

92.7%

mCRPC pembrolizumab Prostate Cancer Foundation pTVG-HP taxane Madison Vaccines, Inc

…AR) would improve the 6-month PFS rate.Methods 60 patients with mCRPC received 3-week cycle treatments with a DNA vaccine (days 1 and…

593 Translational insights from a first-in-human study of NX-1607, an oral CBL-B inhibitor, in advanced solid tumors

jitc · abstract · 2025-11-04 · 2 matching annotations

84.5%

mCRPC advanced solid tumors NX-1607 NX-1607-101 MEDI0680

…ays, including IFN-γ signaling and antigen presentation. In the mCRPC patient subset, specific PBMC transcriptomic profiling revealed…

674 Multi-omic single-cell assessment of castration-resistant prostate cancer patients receiving ¹7 7Lu-PSMA-617 and pembrolizumab shows timing of radioligand therapy alters immune response

jitc · abstract · 2025-11-04 · 2 matching annotations

89.4%

Prostate cancer CRPC mCRPC Metastatic Head and Neck Squamous Cell Carcinoma pembrolizumab Nivolumab Ipilimumab

…Background Prostate cancer, a leading cause of cancer-related death in men, is refractory …

916 A novel anti-TCR Vb targeted bispecific antibody in combination with a poly ADP-ribose polymerase inhibitor (PARPi) enhances anti-tumor immune response in prostate cancer models

jitc · abstract · 2025-11-04 · 2 matching annotations

99.2%

mCRPC prostate cancer TRAMP-C2 Olaparib STAR0602 mSTAR1302 NCT05592626

…Background mCRPC is an advanced disease stage where, regardless of testosterone-…

PARP inhibition combined with a T-cell receptor β chain-directed antibody fusion molecule drives polyclonal antitumor immunity and tumor regression

jitc · abstract · 2026-07-01 · 1 matching annotations

86.1%

Metastatic castration-resistant prostate cancer (mCRPC)mCRPC olaparib STAR0602 mSTAR1302 mSTAR1302-mediated NCT05592626

…Background Metastatic castration-resistant prostate cancer (mCRPC) remains an aggressive disease with limited response to systemic…